KLIFO expands its footprint with the acquisition of medicomp

JANUARY 29, 2024 – Copenhagen (Denmark)

KLIFO A/S, today announced that it will acquire medicomp GmbH, a life science service provider based in Munich, Germany. KLIFO will acquire medicomp’s assets, resources, contracts and customer contacts for an undisclosed amount. Over time, medicomp will begin to operate under the KLIFO brand.

medicomp provides life science services to pharmaceutical, medical device and biotech companies in Germany. Dr Michael Gierend established medicomp in 1985 as a clinical data analysis and data management company. Today, the company offers a wide range of services across all steps of clinical trial handling. medicomp employs 25 experts including project managers, clinical research associates and statisticians. The sale of medicomp to KLIFO comes about as Dr Gierend will hand over the business after more than 34 years of heading up medicomp.

The acquisition of medicomp is part of KLIFO’s strategy to sustain the strong growth it has experienced over the past few years by expanding the company’s operational footprint. KLIFO has been recognised as one of the fastest growing companies in Denmark four years in a row. Establishing a presence in Munich is strategically significant as the city is an important biotech hub in Europe with approximately 250 life sciences companies operating out of Munich.

“Over the past years KLIFO has had a strong collaboration with medicomp, so it seems natural to now incorporate them into the KLIFO family,” explains Alejandra Mørk, chief executive officer for KLIFO. “With its well-established reputation and the extensive expertise of its staff, the acquisition of medicomp supports the KLIFO strategy to become a leading drug development consultancy within Europe. Our goal is to meet our customers’ need for a single expert provider that can support them every step of the way through the increasingly complex drug development journey.”

KLIFO intends to expand the current medicomp service offering in Germany by introducing an end-to-end drug development consultancy, similar to what KLIFO has in Denmark and expanding on their regulatory affairs offering. At the same time, medicomp’s data management and biostatistics capabilities and expertise will be an asset to KLIFO’s existing and future clients.

“KLIFO’s acquisition of medicomp provides a major growth opportunity for both companies through an extended service offering for our clients. Both companies have a long-lasting experience in working together on many of the same projects in different countries. In our line of business, ‘know-how’ is our strongest asset and both KLIFO and medicomp have a history of investing in their people, so I am confident that KLIFO is the right company to bring medicomp and the individuals to the next level,” says Dr Michael Gierend.

The management and staff of both KLIFO and medicomp are committed to ensuring a smooth transition where continuity of business is the top priority.
KLIFO is an established and integrated drug development consultancy providing both consulting and operational services in all areas of clinical research to pharmaceutical and biotech companies. KLIFO is headquartered in Denmark and was established in 1994. Today, with the acquisition of medicomp, the company has approximately 120 highly qualified staff from an array of disciplines.

For more information about KLIFO, visit:
For more information about Medicomp, visit:

For further information about the acquisition, please contact:

Alejandra Mørk
Chief executive officer
Phone: +45 44 222 910
Email: moc.ofilk@kroM.ardnajelA

Michael Engsig
Executive vice president, Drug Development Counselling and Business
Phone: +45 44 222 913
Email: moc.ofilk@gisgnE.leahciM